/
Stats on ER visits should convince FDA safeguards need to remain

Stats on ER visits should convince FDA safeguards need to remain


Stats on ER visits should convince FDA safeguards need to remain

A leading pro-life group argues that if the Food and Drug Administration takes a look at the science, restrictions on use of chemical abortions won't be eliminated.

The FDA is considering lifting restrictions on chemical abortions and is set to announce its decision on December 16. The Charlotte Lozier Institute (CLI), which contends the safety of chemical abortion is "greatly exaggerated," conducted a ground-breaking study on the complications of abortion.

Dr. Jim Studnicki, CLI's vice president of data analytics, tells AFN they looked at reports from the 17 states that pay for abortion through Medicaid regarding emergency room visits post-abortion.

Studnicki, Dr. Jim (Charlotte Lozier Institute) Studnicki

"And what we discovered is that, first of all, emergency room visits following any kind of abortion are increasing dramatically – so much so that by 2015, for every 100 abortions there were approximately 35 emergency room visits," he describes.

Studnicki cites additional statistics indicating that women who undergo chemical abortions are increasingly likely to visit hospitals afterwards. "During the period 2002 to 2015, the rate of emergency room visits for chemical abortion within 30 days went up 507%," he explains.

Researchers also found medical personnel were often reporting abortions as miscarriages. Studnicki contends it isn't possible for a woman to have a miscarriage within 30 days of induced abortion.

"[But these findings] suggest that those women – or the individual physicians in the emergency room – are either not aware of the fact that the woman has had an abortion; or they are not recording the fact that the woman has had an abortion," he states.

Studnicki concludes that the stats, taken as a whole, show that Planned Parenthood's claims that abortions are safe don't stand up to close scrutiny.